Canada markets closed

Certara, Inc. (CERT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.08-0.33 (-2.29%)
At close: 04:00PM EDT
14.08 0.00 (0.00%)
After hours: 07:26PM EDT

Certara, Inc.

100 Overlook Center
Suite 101
Princeton, NJ 08540
United States
609 716 7900
https://www.certara.com

Sector(s)Healthcare
IndustryHealth Information Services
Full Time Employees1,150

Key Executives

NameTitlePayExercisedYear Born
Dr. William F. Feehery Ph.D.CEO & Director1.35MN/A1971
Mr. Leif E. PedersenPres & Chief Commercial Officer625.53kN/A1965
Dr. Robert P. Aspbury Ph.D.Pres of Certara Scientific Software518.09kN/A1972
Dr. Patrick F. Smith Pharm.D.Pres of Drug Devel. Solutions621.58kN/A1971
Mr. John E. Gallagher IIIChief Financial OfficerN/AN/A1973
Mr. Max KanevskyChief Technology OfficerN/AN/AN/A
Prof. Amin Rostami PharmD, Ph.D., FCPChief Scientific OfficerN/AN/AN/A
Mr. Richard M. TraynorSr. VP, Gen. Counsel & Sec.N/AN/A1972
Mr. Ron DiSantisSr. VP of Corp. Devel.N/AN/AN/A
Ms. Sheila Rocchio MBAChief Marketing OfficerN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Corporate Governance

Certara, Inc.’s ISS Governance QualityScore as of September 1, 2023 is 6. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 8; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.